Target Volume Dose Research Articles

Evaluation of dose and anatomy variability for nasopharyngeal carcinoma radiotherapy with a new fully integrated CT-linac

The goal of this study was to investigate the variability of target volume and parotid gland dose distribution for nasopharyngeal carcinoma (NPC), and to explore the shifting patterns of parotid gland centroid and neck radius during radiotherapy. Twenty patients with NPC were enrolled. The target volume dose difference between planning dose and recalculated dose on weekly CT was analyzed. The recalculated doses on every weekly CT were cumulated to assess the difference between delivered dose and planning dose. The relationship of parotid gland centroid deviation with dose was studied, and the shrinking distances of neck radius were calculated for cervical vertebra 1, 2, 3 levels (C1, C2, C3). The ratio of GTVs and CTVs doses on weekly CTs to the doses on planning CT was all above 0.98; the dose of PTVs on weekly CT tended to decrease compared with planning. RMD was defined as the ratio of the mean dose of the left and right parotid glands (L-PG, R-PG) to the planning mean dose. The fitted relationships of RMD and the deviation of centroid (D) for L-PG and R-PG were: RMD=0.37*D+0.98 (R2 = 0.62, p < 0.001) and RMD = 0.33*D+0.97 (R2 = 0.72, p < 0.001), respectively. The order of neck radius shrinking distance at different levels was C1>C2=C3. In this study, we quantitatively analyzed the dosimetric variabilities of target volumes, and established linear models of parotid gland dose and its centroid deviation, which provides fractional and full-course dose evaluation during radiotherapy for NPC.

Defining the potential for sexual structures-sparing for prostate cancer external beam radiotherapy: A dosimetric study

PurposeThe purpose of the study was to evaluate the dosimetric impact of sexual-sparing radiotherapy for prostate cancer, with magnetic resonance-only treatment planning. Material and methodsFifteen consecutive patients receiving prostate cancer radiotherapy were selected. A synthetic CT was generated with a deep learning method from each T2-weighted MRI performed at the time of treatment planning. For each patient, two plans were performed: standard treatment planning and sexual-structures sparing treatment planning. The treatment plan was designed to deliver a dose of 78Gy to the prostate and 50Gy to the seminal vesicles in 2Gy daily fractions, using volumetric arc therapy. Dose–volume histograms were computed to compare treatment plans. ResultsAll plans fulfilled dosimetric objectives and were equivalent regarding planning target volume coverage. The doses delivered to both rectum, bladder, and femoral heads were similar between plans (P=0.20). Sexual-sparing plans enabled to decrease all dosimetric parameters on sexual organs-at-risk. The mean penile bulb dose in sexual-sparing plans was significantly reduced (21.1Gy±20.7 versus 13.4Gy±14.0, P<0.01), however with large variability observed between individuals. The mean dose delivered to the corpora cavernosa was also significantly reduced within sexual-sparing plans (13.1Gy±16.7 versus 8.6Gy±10.4, P<0.01). A significant reduction was also observed in the highest doses delivered to internal pudendal arteries (D10%: 48.4Gy±8.3 versus 33.1Gy±4.6, P<0.05; D5%: 52.0Gy±8.7 versus 36.8Gy±5.5, P<0.05). ConclusionSparing of sexual structures appears feasible, without compromising neither planning target volume coverage nor doses delivered to non-sexual organs at risk. The clinical significance of this dose-reduction requires prospective evaluation.

Dosimetric optimization for dynamic mixed beam arc therapy (DYMBARC).

Non-coplanarity and mixed beam modality could be combined to further enhance dosimetric treatment plan quality. We introduce dynamic mixed beam arc therapy (DYMBARC) as an innovative technique that combines non-coplanar photon and electron arcs, dynamic gantry and collimator rotations, and intensity modulation with photon multileaf collimator (MLC). However, finding favorable beam directions for DYMBARC is challenging due to the large solution space, machine component constraints, and optimization parameters, posing a highly non-convex optimization problem. To establish DYMBARC and solve the pathfinding challenge by employing direct aperture optimization (DAO) to determine the table angles and gantry angle ranges of photon and electron arcs for different clinically motivated cases. The method starts by generating a grid of beam directions based on user-defined resolutions along the gantry and table angle axes for each beam quality considered. Beam directions causing collisions or entering through the end of CT are excluded. For electrons, a fixed source-to-surface distance of 80cm is used to reduce in-air scatter. Electron beam energies with insufficient range to reach the target or beam directions impinging on the table before reaching the patient are excluded. The remaining beam directions form the pathfinding solution space. Promising photon and electron MLC-defined apertures, with associated monitor unit (MU) weights, are iteratively added using a hybrid-DAO algorithm. This algorithm combines column generation to add apertures and simulated annealing to further refine aperture shapes and weights. Apertures are added until the requested number of paths are formed and the user-defined maximum total gantry angle range is reached. Paths are resampled to a finer gantry angle resolution and subject to DAO for simultaneous optimization of beam intensities along the photon/electron arcs. Subsequent final dose calculation and MU weight reoptimization result in a deliverable DYMBARC plan. DYMBARC plans are created for three clinically motivated cases (brain, breast, and pelvis) and compared to DYMBARC variants: colli-DTRT (dynamic collimator trajectory radiotherapy) using non-coplanar photon arcs; and Arc-MBRT (mixed beam radiotherapy) using photons and electrons but restricted to coplanar setup. Additionally, a manually defined volumetric modulated arc therapy (VMAT) setup serves as a reference clinical technique. Dose distributions, dose-volume histograms, and dosimetric endpoints are evaluated. Dosimetric validation with radiochromic film measurements (gamma evaluation, 3% / 2mm (global), 10% dose threshold) is performed on a TrueBeam system in developer mode for one case. While maintaining similar target coverage and homogeneity, DYMBARC reduced mean doses to organs-at-risk compared to VMAT by an average of 3.2, 0.5, and 2.9Gy for the brain, breast, and pelvis cases, respectively. Similar or smaller mean dose reductions were observed for Arc-MBRT or colli-DTRT, compared to VMAT. Electron contributions to the mean planning target volume dose ranged from 2% to 34% for DYMBARC and from 11% to 40% for Arc-MBRT. Measurement validation showed>99.7% gamma passing rate. DYMBARC was successfully established using a dosimetrically optimized pathfinding approach, combining non-coplanarity with mixed beam modality. DYMBARC facilitated the determination of photon and electron contributions on a case-by-case basis, enhancing more personalized treatment modalities.

Knowledge-based planning, multicriteria optimization, and plan scorecards: A winning combination

Background and purposeThe ESTRO 2023 Physics Workshop hosted the Fully-Automated Radiotherapy Treatment Planning (Auto-RTP) Challenge, where participants were provided with CT images from 16 prostate cancer patients (6 prostate only, 6 prostate + nodes, and 4 prostate bed + nodes) across 3 challenge phases with the goal of automatically generating treatment plans with minimal user intervention. Here, we present our team’s winning approach developed to swiftly adapt to both different contouring guidelines and treatment prescriptions than those used in our clinic. Materials and methodsOur planning pipeline comprises two main components: 1) auto-contouring and 2) auto-planning engines, both internally developed and activated via DICOM operations. The auto-contouring engine employs 3D U-Net models trained on a dataset of 600 prostate cancer patients for normal tissues, 253 cases for pelvic lymph node, and 32 cases for prostate bed. The auto-planning engine, utilizing the Eclipse Scripting Application Programming Interface, automates target volume definition, field geometry, planning parameters, optimization, and dose calculation. RapidPlan models, combined with multicriteria optimization and scorecards defined on challenge scoring criteria, were employed to ensure plans met challenge objectives. We report leaderboard scores (0–100, where 100 is a perfect score) which combine organ-at-risk and target dose-metrics on the provided cases. ResultsOur team secured 1st place across all three challenge phases, achieving leaderboard scores of 79.9, 77.3, and 78.5 outperforming 2nd place scores by margins of 6.4, 0.4, and 2.9 points for each phase, respectively. Highest plan scores were for prostate only cases, with an average score exceeding 90. Upon challenge completion, a “Plan Only” phase was opened where organizers provided contours for planning. Our current score of 90.0 places us at the top of the “Plan Only” leaderboard. ConclusionsOur automated pipeline demonstrates adaptability to diverse guidelines, indicating progress towards fully automated radiotherapy planning. Future studies are needed to assess the clinical acceptability and integration of automatically generated plans.

Simultaneous integrated boost-intensity modulated radiation therapy (SIBIMRT) planning for pelvic tumours: dose coverage to target volume and normal tissue sparing.

To evaluate the better radiotherapy plan for pelvic tumours that may achieve a high target coverage dose and low normal tissue tolerance dose using simultaneous integrated boost-intensity-modulated radiation therapy technique. The analytical, cross-sectional, descriptive study was conducted from October 2020 to March 2021 at Al- Amal National Hospital for Cancer Treatment, Baghdad, Iraq, and comprised male pelvic cancer patients aged 50-80 years. Computed tomography scans were randomly selected. For each patient, 4 treatment plans (phases Ι and Π) were generated using the simultaneous integrated boost-intensity-modulated radiation therapy technique while keeping all parameters constant except the number of beams, which were 5, 7, 9 and 11. The optimal and safe dose was defined as the one to cover 95% planning target volume. Homogeneity and conformity indices were used to assess the uniformity of dose distribution in the target volume, and various treatment plans in the same patient were compared. Data was analysed using SPSS 24. There were 15 males with mean age 67.12±2.84 years. There was a significant variance in the target volume dose and organ at risk in the 4 different plans generated using the simultaneous integrated boost-intensitymodulated radiation therapy technique (p<0.05). The 9-beam treatment plan was the best for coverage of tumours and protection of healthy organs assessed through homogeneity and conformity indices (p<0.05). The 9-beam treatment plan showed significant tumour coverage, homogeneity and conformity values, and sparing dose for organs at risk.

Patient, tumour, and dosimetric factors influencing survival in non-small cell lung cancer patients treated with stereotactic ablative body radiotherapy.

We aimed to analyse clinical outcomes of peripheral, early-stage non-small cell lung cancer (NSCLC) patients treated with stereotactic ablative body radiotherapy (SABR), and evaluate potential patient, tumour, and dosimetric variables influencing survival. Data were collected retrospectively from patients treated between September 2012 and December 2016 and followed up until January 2021. Patient demographics, tumour characteristics, SABR dosimetric parameters, and survival data were collected from electronic patient medical records. Descriptive statistics were performed, and SPSS software was used for survival analysis. Eighty-nine patients were included of whom 49.5% were male and 50.5% female. Median age was 74 years. 98.8% of patients had T1-2 tumours and 89.9% underwent 55 Gy in 5 fractions. Median overall survival time was 58.7 months. On uni- and multi-variate analysis, neither patient nor tumour variables showed association with overall survival. However, planning target volume (PTV) and minimum dose to PTV correlated with overall survival. There was a signal for association between mean lung dose and overall survival on multivariate analysis. Our long-term results show SABR is an effective treatment for peripheral, early-stage NSCLC with excellent overall survival, comparable to other series. Our study found only the PTV and minimum dose to PTV had an impact on overall survival, which demonstrates the importance of generating optimal SABR plans. Our work identified lung SABR dosimetric parameters that correlate with survival, which illustrates the importance of producing optimal lung SABR plans.

Evaluation and Comparison of the Dose Received by the Mandible, Maxilla, and Teeth in Two Methods of Three-dimensional Conformal Radiation Therapy and Helical Tomotherapy.

Using three-dimensional conformal radiation treatment (3D-CRT) and helical tomotherapy (HT), this study examines and contrasts the dosage received by the mandible, maxilla, and teeth. Sixteen patients with head-and-neck cancer (H and NC) were the subject of treatment planning at the Seyyed Al-Shohada Hospital in Isfahan, Iran. This study examined target coverage quality, exposure of healthy tissue, and radiation delivery effectiveness. In terms of a number of measures, including D2%, D50%, Dmean, V95%, conformity index (CI), and homogeneity index (HI) for the planning target volume (PTV) and D2%, D98%, Dmean, V95%, CI, and HI for the nodal PTV, HT showed considerable gains over 3D-CRT. The brainstem, D1cc, and D10cc received considerably lower maximum dosages in HT. Measurements of the right and left cochleas (Dmean, V55, and Dmax) revealed decreases in HT, with Dmean revealing the most significant variations. The Dmean and Dmax values for HT significantly decreased in constrictors as well. In terms of several HT-related indicators, the larynx, optic chiasm, optic nerves, oral cavity, mandible, thyroid, and parotid glands all showed considerable decreases. The findings of the comparison of the two treatment approaches revealed that the HT method was more than 50% more effective than the 3D-CRT method in sustaining organs at risk (OARs) and the target volume dose. In general, dosimetric coverage, homogeneity, conformity indices, and the absence of cold and hot patches showed that HT produced targets with greater accuracy than 3D-CRT. In addition, HT outperformed 3D-CRT in protecting important structures (OARs). HT as a result has the potential to be a more effective method of treatment for those with H and NC and involvement of regional lymph nodes.

Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non-small cell lung cancer.

To explore the survival effect of thoracic gross tumor volume (GTV) in three-dimensional (3D) radiotherapy for stage IV non-small cell lung cancer (NSCLC). The data cases were obtained from a single-center retrospective analysis. From May. From 2008 to August 2018, 377 treatment criteria were enrolled. GTV was defined as the volume of the primary lesion and the hilus as well as the mediastinal metastatic lymph node. Chemotherapy was a platinum-based combined regimen of two drugs. The number of median chemotherapy cycles was 4 (2-6), and the cut-off value of the planning target volume (PTV) dose of the primary tumor was 63 Gy (30-76.5 Gy). The cut-off value of GTV volume was 150 cm3 (5.83-3535.20 cm3). The survival rate of patients with GTV <150 cm3 is better than patients with GTV ≥150 cm3. Multivariate Cox regression analyses suggested that peripheral lung cancer, radiation dose ≥63 Gy, GTV <150 cm3, 4-6 cycles of chemotherapy, and CR + PR are good prognostic factors for patients with stage IV non-small cell lung cancer. The survival rate of patients with GTV <150 cm3 was longer than patients with ≥150 cm3 when they underwent 2 to 3 cycles of chemotherapy concurrent 3D radiotherapy (p < 0.05). When performing 4 to 6 cycles of chemotherapy concurrent 3D radiotherapy, there was no significant difference between <150 cm3 and ≥150 cm3. The volume of stage IV NSCLC primary tumor can affect the survival of patients. Appropriate treatment methods can be opted by considering the volume of tumors to extend patients' lifetime to the utmost.

Clinical target volume design and dose in carbon-ion radiation therapy for sinonasal mucosal melanoma

Background and purposeNo guidelines exist for the clinical target volume (CTV) and radiotherapy dose in sinonasal mucosal melanoma (SNMM). Thus, we aimed to determine the carbon-ion radiotherapy (CIRT) CTV and dose for SNMM. Materials and methodsIn total, 135 patients with SNMM who received CIRT were reviewed. The relative biological effectiveness-weighted dose was 57.6 or 64 Gy in 16 fractions. CTV was classified into small CTV, which included the gross tumor and visible melanosis with a certain margin, and extended CTV, which included the tumor site and adjacent anatomical structures. Local recurrence (LR) patterns were pattern I, II, and III, defined as recurrence over the gross tumor, visible melanosis and subclinical area, which would be covered if extended CTV was applied, and outside the extended CTV, respectively. ResultsThe 5-year LR rate was 35.3 %. The prescribed dose was not a significant risk factor for pattern I LR; however, 57.6 Gy for a large tumor was insufficient for local control. Using an extended CTV was significantly associated with a lower risk of pattern II LR, and these recurrences did not occur in regions that received > 40 Gy. The 5-year pattern III LR rate was 6.4 %. ConclusionUtilizing an extended CTV in CIRT for SNMM is appropriate even for small tumors. Using a smaller CTV after an extended CTV of at least 40 Gy is recommended to reduce adverse events. Although the optimal dose for gross tumors remains unclear, the latest technology with 64 Gy showed good outcomes.

Does a peer review group consensus process for MR-Linac patients affect clinical care? Evaluation of impact and feasibility

Background and purposePeer review is an important component of quality assurance in radiotherapy. To our knowledge, there are no studies reporting on the feasibility and outcomes of the peer review process for magnetic resonance (MR) guided radiotherapy (MRgRT) on the MR linear accelerator (MR-Linac) despite the planning complexity involved and its evolving clinical indications. This study aimed to quantify the rate of change in treatment plans post-peer review and the time and resources required. Materials and methodsFifty-five cases presented at weekly MR-Linac peer review meetings across two centres from 8 June to 21September 2023 were prospectively collected. Cases were analysed to determine the rate and extent of plan changes based on the Peer Review Audit Tool for radiation oncology (PRAT) developed by the Royal Australian and New Zealand College of Radiologists (RANZCR). ResultsPeer review resulted in changes to 36.4 % of treatment plans (n = 20), with 3.6 % (n = 2) having major changes requiring deferment of treatment. The most frequent changes were to organs at risk (OAR) volumes involving both delineation and increased OAR sparing (16.4 %, n = 9), total dose and fractionation (10.9 %, n = 6) and target volume dose coverage (5.5 %, n = 3). Patients with SBRT plans (39.1 % cf 22.2 %), oligometastatic/oligoprogressive sites (38.1 % cf 30.7 %) and reirradiation cases (41.2 % cf 34.2 %) had higher rates of change. Cases took a mean of 7 min (range 2–15 minutes) to discuss. ConclusionThe high rates of plan changes support the value of peer review in MRgRT. We recommend, where possible that all MRgRT cases, particularly those involving SBRT plans, oligometastatic/oligoprogressive sites, and/or reirradiation, be subject to peer review.

Evolving Prostate Cancer Radiotherapy: Exploring Gonadal Doses in 3DCRT and IMRT with Testicular Shielding

Objective: To compare the dosimetry of IMRT versus 3DCRT in prostate cancer, with a focus on testicular dose using lead testicular shielding. Materials and Methods: From January 2021 to January 2022, twenty patients with localized prostate cancer underwent IMRT treatment. Plans for 3DCRT were generated for each patient. Comparison was made between 3D-CRT and IMRT regarding target volume dose uniformity, sparing of critical organs, and testicular doses. Results: Significant differences were observed in dose uniformity and sparing of critical organs between the two modalities (p&lt;0.005), demonstrating the superiority of IMRT over 3DCRT. However, with lead testicular shielding, comparable testicular doses were achieved with both techniques. Conclusion: IMRT offers superior dosimetric advantages compared to 3DCRT. Nevertheless, the testicular dose remains nearly equivalent between the two techniques when utilizing lead testicular shielding.

Evaluation of the offset couch parameter between kilovoltage on-board imaging and cone-beam computed tomography in patients with prostate cancer

Background: External Beam Radiation Therapy (EBRT) is a curative therapy technique for prostate cancer. Since the prostate is unstable and surrounded by the bladder and rectum, precision of the target location is critical. Image Guided Radiation Therapy (IGRT) can improve treatment precision. The bladder and rectum may alter volume during IGRT, shifting the prostate’s position and resulting in missed target volume doses and extra organs at risk (OARs) doses. Objective: To assess setup error and residual error during patient positioning, as well as the current IGRT protocol efficiency, in prostate cancer patients while recommending a planning target volume (PTV) margin. Materials and methods: The offset couch parameter of on-board imaging (OBI) and cone-beam computed tomography (CBCT) was computed to determine the error distribution, magnitude, and error difference between treatment phases. The systematic and random errors were calculated using the van Herk equation to determine the planning target volume (PTV) margin. Results: The setup error was -0.86 to 0.25 mm, and the residual error was -0.15 to 0.32 mm. The couch displacement percentage for OBI was 29.44% to 58.89%, and for CBCT was 8.10% to 34.12%. The systematic error was 1.65 to 3.21. The random error was 1.78 to 3.29. The setup error was greatest in the longitudinal (Lng) direction, residual error was greatest in the vertical (Vrt) direction, and systematic and random error were greatest in the Vrt and lateral (Lat) direction, respectively. The PTV margin was greatest in the Vrt direction, while the Lng direction was the narrowest margin for every treatment phase. Conclusion: The highest setup error occurs in the Lng direction for all treatment phases. For the 46 Gy and 60 Gy phases, the highest residual error is in the Vrt direction. However, in the 78 Gy phase, the error is relatively close to 0.01mm in every direction. The current IGRT protocol is effective in detecting setup and residual errors. The 78 Gy phase has the greatest PTV margin, whereas the 46 Gy phase shows the narrowest margins in all directions.

Effectiveness of multi-criteria optimization in combination with knowledge-based modeling in radiotherapy of left-sided breast including regional nodes

Multi-criteria optimization (MCO) is a method that was added to treatment planning to create high-quality treatment plans. This study aimed to investigate the effectiveness of MCO in combination with knowledge-based planning (KBP) in radiotherapy for left-sided breasts, including regional nodes. Dose/volume parameters were evaluated for manual plans (MP), KBP, and KBP + MCO. Planning target volume doses of MP had better coverage while KBP + MCO plans demonstrated the lowest organ at risk doses. KBP and KBP + MCO plans had increasing complexity as expressed in the number of monitor units.

Determining the library size for the optimal output plan in the RapidPlan knowledge-based planning system using multicriteria optimization.

The aim of this study was to determine the number of trade-off explored (TO) library plans required for building a RapidPlan (RP) library that would generate the optimal clinical treatment plan. We developed 2 RP models, 1 each for the 2 clinical sites, head and neck (HN) and cervix. The models were created using 100 plans and were validated using 70 plans (VP) for each site respectively. Each of the 2 libraries comprising 100 TO plans was divided into 5 different subsets of library plans comprising 20, 40, 60, 80, and 100 plans, leading to 5 different RP models for each site. For every validation patient, a TO plan (TO_VP) was created. For every patient, 5 RP plans were automatically generated using RP models. The dosimetric parameters of the 6 plans (TO_VP + 5 RP plans) were compared using Pearson correlation and Greenhouse-Geisser analysis. Planning target volume (PTV) dose volume parameters PTVD95% in 6 competing plans varied between 97.6 ± 0.7% and 98.1 ± 0.6% in HN cases and 98.8 ± 0.3% and 99.0 ± 0.4% in cervix cases. Overall, for both sites, the mean variations in organ at risk (OAR) doses or volumes were within 50 cGy, 0.5%, and 0.2 cc between library plans, and if TO_VP was included the variations deteriorated to 180 cGy, 0.4%, and 15 cc. All OARs in both sites, except D0.1 ccspine, showed a statistically insignificant variation between all plans. Dosimetric variation among various output plans generated from 5 RP libraries is minimal and clinically insignificant. The optimal output plan can be derived from the least-weighted library consisting of 20 plans. This article shows that, when the constituent plans are subjected to trade-off exploration, the number of constituent plans for a knowledge-based planning module is not relevant in terms of its dosimetric output.

Increasing pediatric radiation oncology capacity in sub-saharan Africa using technology: a pilot of a pediatric radiation oncology virtual training course

BackgroundThe shortage of skilled healthcare professionals in pediatric oncology and the limited access to training programs remain significant challenges in Nigeria and sub-Saharan Africa. The the Pediatric Radiation Oncology (Virtual) Course, ‘PedROC’ project aims to contribute to improving pediatric cancer outcomes in Nigeria by increasing the capacity of radiation oncology professionals. To address the gap in access to pediatric radiation oncology professional development, the PedROC project was created, harnessing technology to improve radiation oncology training via a curriculum delivered through web-conferencing. This study aimed to evaluate the effectiveness of the PedROC pilot in enhancing the capacity, confidence, and skill of radiation oncologists in decision-making, prescribing, and treatment planning of radiotherapy for children diagnosed with cancer.MethodsA multidisciplinary faculty of specialists in radiation oncology, pediatric oncology, oncology nursing, radiation therapy technology, and medical physics collaborated to identify the key learning needs in pediatric radiation oncology in the country. The team collaborated to develop a comprehensive curriculum covering the most common pediatric cancers in sub-Saharan Africa for the training program. The training course was conducted over two days, delivering twenty-four half-hour sessions for a total of 12 h, from July 31 to August 01, 2021.ResultsAnalysis of pre and post - training surveys showed a significant increase in self-reported confidence measures across all domains among radiation oncologists. The program successfully improved participants’ knowledge and confidence levels in managing common pediatric cancers using radiotherapy, particularly addressing radiotherapy-specific issues such as appropriate dose, target volume delineation, treatment planning, dose constraints, and plan evaluation.ConclusionThe PedROC pilot showed the efficacy of this model in enhancing the capacity and confidence of radiation oncology professionals involved in the treatment of pediatric cancer. The findings indicate that technology holds significant potential to increase pediatric radiation oncology capacity in Africa, ensuring improved access to proper treatment and ultimately improving pediatric cancer outcomes.

DOSIMETRIC COMPARISON OF INTENSITY-MODULATED RADIATION THERAPY (IMRT) AND VOLUMETRIC-MODULATED ARC THERAPY (VMAT) IN RECTAL CANCER PATIENTS: A COMPREHENSIVE ANALYSIS

This study aimed to conduct a thorough dosimetric comparison between two advanced radiotherapy techniques, Intensity-Modulated Radiation Therapy (IMRT) and Volumetric-Modulated Arc Therapy (VMAT), to ascertain the superior modality in terms of dose distribution and organ-at-risk sparing for rectal cancer patients. Thirty-three patients with ECOG performance status 1, aged between 18 to 60 years, diagnosed with Stage II to III rectal cancer, were included in this prospective study. Each patient underwent treatment planning with IMRT and VMAT techniques using Varian system simulation computed tomography scans. The dosimetric analysis encompassed the evaluation of target volume dose homogeneity, conformity, and doses to at-risk organs. The dosimetric comparison was conducted utilizing seven-field IMRT and dual arc VMAT plans. Statistical analysis was performed using paired t-tests and SPSS 20 software. Treatment plan constraints adhered to the RTOG 9406 guidelines, ensuring adequate planning target volume (PTV) coverage, homogeneity index, conformity index, and dose limits for organs at risk, including small bowel V20 (&lt;200cc), bladder V45 (&lt;21Gy), and femoral head V50 (≤30 Gy). Volumetric arc therapy plans demonstrated superior dose homogeneity to fixed-field intensity-modulated plans (p-value = 0.04), particularly in femoral head dose-limiting toxicity (p-value = 0.00). However, intensity-modulated therapy exhibited equivalent or superior performance in other evaluated parameters. Our findings suggest that while VMAT offers advantages in PTV coverage homogeneity and femoral head dose-limiting toxicity, IMRT remains competitive and potentially preferable in certain dosimetric aspects. The choice between IMRT and VMAT should be carefully considered based on individual patient characteristics and treatment goals. This comprehensive dosimetric comparison contributes valuable insights into optimizing radiotherapy planning for rectal cancer patients, potentially guiding clinical decision-making and improving treatment outcomes.

Dosimetric Evaluation of Target Motion Effects in Spot-Scanning Proton Therapy: A Phantom Study

PurposeTo evaluate intrafractional motion effects as a function of peak-to-peak motion and period during single-field, single-fraction and single-field, multifraction irradiation of the moving target in spot-scanning proton therapy. Materials and MethodsAn in-house dynamic phantom was used to simulate peak-to-peak motion of 5, 10, and 20 mm with periods of 2, 4, and 8 seconds. The dose distribution in the moving target was measured using radiochromic films. During the perpendicular motion, the film was fixed and moved perpendicular to the beam direction without changing the water equivalent thickness (WET). During longitudinal motion, the film was fixed and moved along the beam direction, causing a change in WET. Gamma index analysis was used with criteria of 3%/3 mm and 3%/2 mm to analyze the dose distributions. ResultsFor single-fraction irradiation, varying the period did not result in a significant difference in any of the metrics used (P > .05), except for the local dose within the planning target volume (P < .001). In contrast, varying peak-to-peak motion was significant (P < .001) for all metrics except for the mean planning target volume dose (P ≈ .88) and the local dose (P ≈ .47). The perpendicular motion caused a greater decrease in gamma passing rate (3%/3 mm) than WET variations (65% ± 5% vs 85% ± 4%) at 20 mm peak-to-peak motion. ConclusionThe implementation of multifraction irradiation allowed to reduce hot and cold spots but did not reduce dose blurring. The motion threshold varied from 7 to 11 mm and depended on the number of fractions, the type of motion, the acceptance criteria, and the calculation method used.

Dosimetric evaluation of ultrafractionated dose escalation with simultaneous integrated boost to intraprostatic lesion using 1.5-Tesla MR-Linac in localized prostate cancer.

We analyzed a dose escalation of 36.25 Gy to the entire prostate and a dose increment up to 40 Gy with 1.25 Gy increments to intraprostatic lesion (IPL) using simultaneous integrated boost (SIB) in five fractions. Eighteen low- and intermediate-risk prostate cancer patients treated with 1.5T MR-Linac were retrospectively evaluated. The same planning computed tomography (CT) images generated four plans: no SIB, 37.5 Gy SIB, 38.75 Gy SIB, and 40 Gy SIB. In four plans, planning target volume (PTV) doses, organ at risk (OAR) doses, and PTV-SIB homogeneity index (HI), gradient index (GI) and conformity index (CI) were compared. All plans met the criteria for PTV and PTV-SIB coverage. PTV 40 Gy plan has higher maximum PTV and PTV-SIB doses than other plans. The PTV HI was significantly higher in the SIB 40 Gy plan (0.135 ± 0.007) compared to SIB 38.75 Gy plan (0.099 ± 0.007; p = 0.001), SIB 37.5 Gy (0.067 ± 0.008; p < 0.001), and no SIB plan (0.049 ± 0.010; p < 0.001), while there were no significant differences in HI, GI and CI for PTV-SIB between three plans. Four rectum and bladder plans had similar dosimetric parameters. The urethra D5 was significantly higher in SIB 40 Gy plan compared to no SIB plan (37.7 ± 1.1 Gy vs. 37.0 ± 0.7 Gy; p = 0.009) and SIB 37.5 Gy plan (36.9 ± 0.8 Gy; p = 0.008). There was no significant difference in monitor units between the four consecutive plans. Ultra-hypofractionated dose escalation to IPL up to 40 Gy in 5 fractions with a 1.5-T MR-linac is dosimetrically feasible, potentially paving the way for clinical trials.

Adjuvant holmium-166 radioembolization after radiofrequency ablation in early-stage hepatocellular carcinoma patients: a dose-finding study (HORA EST HCC trial)

PurposeThe aim of this study was to investigate the biodistribution of (super-)selective trans-arterial radioembolization (TARE) with holmium-166 microspheres (166Ho-MS), when administered as adjuvant therapy after RFA of HCC 2–5 cm. The objective was to establish a treatment volume absorbed dose that results in an absorbed dose of ≥ 120 Gy on the hyperemic zone around the ablation necrosis (i.e., target volume).MethodsIn this multicenter, prospective dose-escalation study in BCLC early stage HCC patients with lesions 2–5 cm, RFA was followed by (super-)selective infusion of 166Ho-MS on day 5–10 after RFA. Dose distribution within the treatment volume was based on SPECT-CT. Cohorts of up to 10 patients were treated with an incremental dose (60 Gy, 90 Gy, 120 Gy) of 166Ho-MS to the treatment volume. The primary endpoint was to obtain a target volume dose of ≥ 120 Gy in 9/10 patients within a cohort.ResultsTwelve patients were treated (male 10; median age, 66.5 years (IQR, [64.3–71.7])) with a median tumor diameter of 2.7 cm (IQR, [2.1–4.0]). At a treatment volume absorbed dose of 90 Gy, the primary endpoint was met with a median absorbed target volume dose of 138 Gy (IQR, [127–145]). No local recurrences were found within 1-year follow-up.ConclusionAdjuvant (super-)selective infusion of 166Ho-MS after RFA for the treatment of HCC can be administered safely at a dose of 90 Gy to the treatment volume while reaching a dose of ≥ 120 Gy to the target volume and may be a favorable adjuvant therapy for HCC lesions 2–5 cm.Trial registrationClinicaltrials.gov NCT03437382. (registered: 19-02-2018)

Dosimetric advantages for cardiac substructures in radiotherapy of esophageal cancer in deep-inspiration breath hold

BackgroundRadiotherapy is one of the main treatment options for patients with esophageal cancer; however, it has been linked with an increased risk of cardiac toxicities. In the current study, we evaluated the effect of planning the radiation in deep-inspiration breath hold (DIBH) on the dose sparing of cardiac substructures and lung.Materials and methodsIn this study, we analyzed 30 radiation therapy plans from 15 patients diagnosed with esophageal cancer planned for neoadjuvant radiotherapy. Radiation plans were generated for 41.4 Gy and delivered in 1.8 Gy per fraction for free-breathing (FB) and DIBH techniques. We then conducted a comparative dosimetric analysis, evaluating target volume coverage, the impact on cardiac substructures, and lung doses across the two planning techniques for each patient.ResultsThere was no significant disparity in target volume dose coverage between DIBH and FB plans. However, the Dmean, D2%, and V30% of the heart experienced substantial reductions in DIBH relative to FB, with values of 6.21 versus 7.02 Gy (p = 0.011), 35.28 versus 35.84 Gy (p = 0.047), and 5% versus 5.8% (p = 0.048), respectively. The Dmean of the left ventricle was notably lower in DIBH compared to FB (4.27 vs. 5.12 Gy, p = 0.0018), accompanied by significant improvements in V10. Additionally, the Dmean and D2% of the left coronary artery, as well as the D2% of the right coronary artery, were significantly lower in DIBH. The dosimetric impact of DIBH on cardiac substructures proved more advantageous for middle esophageal (ME) than distal esophageal (DE) tumors.ConclusionRadiotherapy in DIBH could provide a method to reduce the radiation dose to the left ventricle and coronaries, which could reduce the cardiac toxicity of the modality.